A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Recruiting
18 years - 99 years
All
Phase
2
5 participants needed
1 Location
Brief description of study
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients will be enrolled from up to 70 investigational sites in the US, Canada, Japan, Taiwan, and South Korea.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Brain Neoplasms, Glioblastoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828092
